Replimune (REPL) Free Cash Flow (2017 - 2026)
Replimune (REPL) reported Free Cash Flow of -$56.2 million for Q1 2026, down 4.94% on a YoY basis from -$59.2 million in Q1 2025, and up 14.5% sequentially from -$65.8 million in Q4 2025.
Replimune (REPL) Free Cash Flow (2017 - 2026) Analysis & Trends
Replimune (REPL) has 10 years of Free Cash Flow data on file, last reported at -$56.2 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 4.94% year-over-year to -$56.2 million; the trailing twelve-month figure through Mar 2026 stood at -$280.4 million (down 45.73% YoY), and the FY2026 full-year result was -$280.4 million, down 45.73% from the prior year.
- Free Cash Flow advanced to -$56.2 million in Q1 2026, from -$65.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$21.8 million in Q1 2022 to a low of -$79.8 million in Q2 2025.
- A 5-year average of -$47.9 million and a median of -$47.3 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow gained 5.91% in 2024 and slumped 93.13% in 2025, its largest moves.
- Tracing REPL's Free Cash Flow over 5 years: stood at -$29.1 million in 2022, then slumped by 61.22% to -$47.0 million in 2023, then decreased by 0.6% to -$47.3 million in 2024, then sank by 39.16% to -$65.8 million in 2025, then rose by 14.5% to -$56.2 million in 2026.
- Business Quant data shows REPL's Free Cash Flow at -$56.2 million in Q1 2026, -$65.8 million in Q4 2025, and -$78.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | -56.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.24 Mn |
| Mar 31, 2026 | -56.24 Mn |
| Dec 31, 2025 | -65.78 Mn |
| Dec 31, 2025 | -65.78 Mn |
| Sep 30, 2025 | -78.65 Mn |
| Sep 30, 2025 | -78.65 Mn |
| Jun 30, 2025 | -79.76 Mn |
| Jun 30, 2025 | -79.76 Mn |
| Mar 31, 2025 | -53.59 Mn |
| Mar 31, 2025 | -53.59 Mn |
| Dec 31, 2024 | -47.27 Mn |
| Dec 31, 2024 | -47.27 Mn |
| Sep 30, 2024 | -40.72 Mn |
| Sep 30, 2024 | -40.72 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Mar 31, 2024 | -51.83 Mn |
| Mar 31, 2024 | -51.83 Mn |
| Dec 31, 2023 | -46.99 Mn |
| Dec 31, 2023 | -46.99 Mn |